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Abstract
Background: Contradicting results on the effect of abacavir (ABC) on hepatitis C virus (HCV) treatment
responses in HIV/HCV co-infected patients have been reported. We evaluated the influence of ABC on the
response to pegylated interferon (pegIFN) and ribavirin (RBV)-containing HCV treatment in HIV/HCV
co-infected patients in a large European cohort collaboration, including data from different European
countries.
Methods: HIV/HCV co-infected patients were included if they were aged ≥16 years, received pegIFN alfa-2a
or 2b and RBV combination treatment and were enrolled in the COHERE cohort collaboration. Logistic
regression was used to evaluate the impact of abacavir on achieving a sustained virologic response (SVR)
to HCV treatment.
Results: In total 1309 HIV/HCV co-infected patients who had received HCV therapy were included, of
whom 490 (37 %) had achieved an SVR. No statistically significant difference was seen for patients using
ABC-containing regimens compared to patients using an emtricitabine + tenofovir (FTC + TDF)-containing
backbone, which was the most frequently used backbone. In the multivariate analyses, patients using a
protease inhibitor (PI)-boosted regimen were less likely to achieve an SVR compared to patients using a
non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen (OR: 0.61, 95 % CI: 0.41–0.91). The
backbone combinations zidovudine&lamivudine (AZT + 3TC) and stavudine&lamivudine (d4t + 3TC) were
associated with lower SRV rates (0.45 (0.24–0.82) and 0.46 (0.22–0.96), respectively).
Conclusion: The results of this large European cohort study validate that SVR rates are generally not affected by
ABC. Use of d4T or AZT as part of the HIV treatment regimen was associated with a lower likelihood of achieving
an SVR.
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Background
Until recently, treatment for hepatitis C (HCV) con-
sisted of a combination of pegylated interferon (pegIFN)
and ribavirin (RBV), combined more recently with boce-
previr and telaprevir or with some of the new direct-
acting antivirals (DAA)-containing regimens. In HIV/
HCV co-infected patients, treatment for HCV is often ad-
ministrated concomitantly with combination antiretroviral
therapy (cART).
Earlier studies have reported contradicting results re-
garding the effect of an abacavir-based cART regimen
(ABC) on HCV treatment response. For example, some
studies found ABC has a negative effect on sustained vi-
rologic response (SVR) in the presence of HCV therapy
[1–3]. This may be because RBV and ABC share intra-
cellular pathways [4], which could, theoretically, affect
RBV drug concentrations and therefore the effectiveness
of RBV. However, other studies found no difference in
SVR between patients who received an ABC-containing
regimen in combination with HCV treatment and those
who did not use ABC concomitantly with HCV treat-
ment [5–8]. These discrepancies might be due to the
relatively small samples sizes used in the above-
mentioned studies. One larger study, conducted by
Berenguer et al. has already been carried out and found
that ABC was not associated with a lower response to
HCV treatment [9].
This issue of contradicting results regarding the inter-
action between ABC and RBV remains important for
two reasons. First, even in interferon-free regimens, RBV
will often be used with a large number of new DAAs.
Furthermore, following the introduction of the HIV inte-
grase inhibitor dolutegravir, which is co-formulated with
ABC/3TC in a fixed-dose combination, use of ABC with
3TC is expected to increase. Therefore, to validate the
results of the earlier large cohort study by Berenguer et
al. we aimed to examine the influence of ABC on the re-
sponse to pegIFN and RBV-containing HCV treatment
in HIV/HCV co-infected patients in a large European




Individuals included in this study were enrolled in HIV co-
horts participating in the Collaboration of Observational
HIV Epidemiological Research in Europe (COHERE). CO-
HERE is a collaboration of 33 cohorts across Europe and
is part of the EuroCoord network (www.cohere.org and
www.EuroCoord.net). The aim of COHERE is to conduct
epidemiological research into the prognosis and outcome
of HIV-infected individuals, which the individual partici-
pating cohorts cannot address themselves because of small
sample sizes. Participating cohorts were approved by a
local ethics committee or institutional review board.
The study included all HIV-positive individuals with a
positive HCV RNA test result who were aged 16 years
or older at the time of HIV diagnosis and who had
started cART after 1 January 1998. Twelve cohorts
across 9 European countries, totalling 1309 patients, pro-
vided data for the present analysis: AHIVCOS (n = 39),
AMACS (n = 9), ATHENA (n = 140), BONN/COLOGNE
(n = 3), EUROSIDA (n = 219), HEPAVIH (n = 287),
ICONA (n = 102), MODENA (n = 37), PISCIS (n = 49),
The Swiss Cohort Study (n = 285), St Pierre Cohort
Brussels (n = 25), VACH (n = 114). Participating cohorts
adhere to the local ethics requirements, cohorts with
ethics approval and individual patient written informed
consent are AHIVCOS, AMACS, HEPAVIH, ICONA,
MODENA, The Swiss Cohort Study, Eurosida and PISCIS.
The remaining cohorts did not require ethics approval
according to the national legislation (Further details of
ethical requirements can be found in Additional file 1). All
patients included in the present analysis received anti-
HCV treatment that included the combined use of pegIFN
alfa-2a or 2b and RBV at standard doses, with a usual dur-
ation of 24 or 48 weeks, depending on HCV genotype.
Data on the use of boceprevir and telaprevir was not avail-
able at the time of database closure. As treatment re-
sponse in patients with an acute HCV infection might
differ from the treatment response in chronically infected
patients, patients with less than 6 months between the
first available positive HCV test result and the start of
anti-HCV treatment (i.e., acute HCV infection) were
excluded (n = 183). To assess the extent of liver fibrosis,
aspartate amino transferase-to-platelet ratio (APRI) scores
were calculated. APRI is a non-invasive method to assess
liver fibrosis that combines AST levels and platelets
counts [10]; an APRI score >1.5 correlates with severe
fibrosis. The main outcome of interest was SVR, de-
fined as a negative HCV RNA test result 24 weeks
after treatment discontinuation in patients treated for
chronic HCV infection.
Statistical analysis
Logistic regression was used to identify factors associated
with achieving SVR. Treatment of HIV was categorised as
protease inhibitor (PI)-unboosted, PI-boosted, non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based,
PI/NNRTI-based regimens and a fifth category including
patients who had started cART after starting HCV
treatment. The NRTI backbone was categorised ac-
cording to the most commonly-used combinations:
abacavir + lamivudine (ABC + 3TC), zidovudine + lamivu-
dine (AZT + 3TC), emtricitabine + tenofovir (FTC + TDF),
tenofovir + lamivudine (TDF + 3TC), tenofovir + abacavir
(TDF +ABC), stavudine + lamivudine (d4T + 3TC), other
combinations, and, finally, a separate group of 242
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patients who started cART after receiving HCV treatment.
To account for the shift from fixed dosing of RBV to
weight-based use of RBV, we assumed that most patients
received weight-based RBV doses from 2006 onwards and,
therefore, analyses were adjusted for calendar year of start-
ing HCV treatment.
Baseline characteristics of patients achieving an SVR
were compared to non-responders using Student’s t-test
for the continuous variables and the Chi-square test
for the categorical variables. Predictors for achieving
an SVR were assessed by calculating odds ratios (OR)
with a 95 % confidence interval (CI) using a logistic
regression model. Multivariate models were built
using forward-stepwise techniques. Variables with a p-
value <0.2 in the univariate analyses were considered
as potential independent determinants and included
in the multivariate analysis. A p-value <0.05 was con-
sidered statistically significant. Interactions in the final




We analysed data from 1309 HIV-infected patients with
a chronic HCV infection who had been prescribed a
combination of pegIFN and RBV between 1998 and
2011. The most common genotype was HCV genotype 1
(n = 536, 40 %) (Table 1). The median duration of anti-
HCV treatment was 31 weeks (inter quartile range
(IQR): 16–49). Of the 1309 patients, 868 completed the
full course of therapy (i.e., 24–48 weeks) with pegIFN
and RBV, whereas 441 prematurely discontinued treat-
ment before week 24 because of side effects or lack of
virologic response. The proportion of patients who dis-
continued HCV treatment before week 24 was higher
among patients on PI and PI-boosted regimens (42 and
38 %, respectively) compared to patients on an NNRTI-
containing regimen (30 %, p = 0.09). The proportion of
patients who prematurely discontinued HCV treatment
did not differ between the different NRTI-backbone
combinations (p = 0.23). Haemoglobin levels were
more likely to drop by more than 2.5 g/dl compared
to baseline in patients who prematurely discontinued
HCV treatment (46 %) than in those who received
HCV treatment for 24 or 48 weeks (31 and 23 %, re-
spectively; p < 0.0001).
Baseline clinical characteristics at the start of HCV
treatment of the included patients are shown in Table 1.
Thirty-four percent of the patients used a PI-boosted
cART regimen. A combination of FTC + TDF was the
most frequently used NRTI backbone (20 %). In total,
233 patients used an ABC-containing NRT combination:
189 used ABC + 3TC (14 %) and 44 used ABC + TDF
(3 %).
SVR
In total, 490 (37 %) patients achieved SVR. The propor-
tion of patients with a baseline CD4 cell count ≥500
cells/μl was significantly higher among patients who
achieved an SVR (41 % vs 35 %; p = 0.02). Patients with
genotype 1 or 4 were significantly less likely to achieve
SVR than patients with genotypes 2 or 3 (p < 0.0001).
The SVR rates ranged from 30 % for patients on a
regimen that included a PI and an NNRTI to 46 % for
those who were treated with an NNRTI-containing com-
bination (p = 0.03). When stratified according to NRTI-
backbone, the SVR rate was 24 % amongst patients using
a d4T&3TC backbone, and the SVR rate was 48 % in pa-
tients using a TDF&3TC backbone. The SVR rate was
38 % for patients with a ABC&AZT backbone and 39 %
for those with a TDF&ABC backbone.
Predictors of SVR
Table 2 shows the predictive factors for SVR in HCV/
HIV co-infected patients receiving anti-HCV treatment.
In the univariate analyses, ABC-containing backbones
were not associated with a higher or lower likelihood of
achieving an SVR. Longer duration of HCV treatment
compared to less than 24 weeks of treatment, men who
have sex with men, HCV genotypes 2 and 3, lower APRI
score, and a larger decline in haemoglobin levels were
associated with a higher likelihood of achieving an SVR.
Starting HCV treatment before 2003 was significantly
associated with a lower likelihood of achieving an SVR
compared to starting in or after 2006. Patients who
started between 2003 and 2005 were non-significantly
less likely to achieve an SVR. Patients using a PI-boosted
cART regimen or an AZT + 3TC NRTI backbone were
also less likely to achieve an SVR.
In the multivariate analyses, after adjustment for dif-
ferences in clinical and demographic variables, there
remained no association between ABC-containing regi-
mens and a higher or lower likelihood of achieving an
SVR. A boosted PI regimen remained significantly asso-
ciated with a lower probability of achieving an SVR com-
pared to NNRTI-based regimens. Overall, the different
backbones, and most importantly the use of ABC, were
not associated with a low SVR after adjustment for dif-
ferences in clinical and demographical variables, with
the exception of the AZT + 3TC and d4t + 3TC combi-
nations. Patients using these backbones were less likely
to achieve an SVR (0.45 (0.24–0.82) and 0.46 (0.22–
0.96), respectively). No statistically significant difference
was seen between patients using ABC -containing regi-
mens and those using an FTC + TDF-containing back-
bone. No statistically significant difference was observed
between patients who started cART after receiving HCV
treatment and those using an FTC + TDF-containing
backbone. Finally, earlier calendar year of starting HCV
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Table 1 Demographic and clinical characteristics at start of anti-hepatitis C virus (HCV) treatment of chronically HIV/HCV co-infected
patients, 1998-2011
Sustained virologic response
Total No Yes p-value
Number of patients (%) 1309 819 (63)a 490 (37)a
Age baseline, years 42 (38–46) 42 (38–46) 42 (37–46) 0.04
Baseline BMI <0.0001
< 25 329 (25b) 234 (71) 95 (29)
> =25 123 (9) 96 (78) 27 (22)
Unknown 857 (66) 489 (57) 368 (43)
Gender 0.57
Male 960 (73) 605 (63) 355 (37)
Female 349 (39) 214 (61) 135 (39)
HIV transmission route: 0.05
Men who have sex with men 175 (13) 91 (52) 84 (48)
Male, injection drug use (IDU) 595 (45) 393 (66) 202 (34)
Female IDU 209 (16) 127 (61) 82 (39)
Male heterosexual 84 (6) 55 (65) 29 (35)
Female heterosexual 96 (7) 62 (65) 34 (35)
Male other/unknown 106 (8) 66 (62) 40 (38)
Female other/unknown 44 (3) 25 (57) 19 (43)
Region of origin: 0.06
Western 1101 (84) 700 (64) 401 (36)
Other 116 (9) 72 (62) 44 (38)
Unknown 92 (7) 47 (51) 45 (49)
CD4 at baseline (cells/μl)
0–349 264 (20) 163 (62) 101 (38) 0.02
350–499 306 (23) 194 (63) 112 (37)
> =500 491 (38) 288 (59) 203 (41)
Missing 248 (19) 174 (70) 74 (30)
Nadir CD4 (cells/ μl) <0.001
< 200 689 (53) 434 (63) 255 (37)
> =200 583 (45) 381 (65) 202 (35)
Missing 37 (3) 4 (11) 33 (89)
HIV RNA levels at baseline (copies/ml) 0.99
< =400 1082 (83) 677 (63) 405 (37)
> 400 227 (17) 142 (63) 85 (37)
Hepatitis B virus co-infection 0.64
No 1214 (93) 762 (63) 452 (37)
Yes 53 (4) 30 (57) 23 (43)
Unknown 42 (3) 27 (64) 14 (33)
HCV RNA load at baseline <0.0001
< 600,000 222 (17) 99 (45) 123 (55)
≥ 600,000 724 (55) 485 (67) 239 (33)
Missing 363 (28) 235 (65) 128 (35)
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Table 1 Demographic and clinical characteristics at start of anti-hepatitis C virus (HCV) treatment of chronically HIV/HCV co-infected
patients, 1998-2011 (Continued)
HCV genotypes <0.0001
1 82 (6) 53 (65) 29 (35)
1a 307 (23) 234 (76) 83 (27)
1b 147 (11) 108 (73) 39 (27)
2&3 315 (24) 154 (49) 161 (51)
4 143 (11) 103 (72) 40 (28)
Other/unknown 315 (24) 177 (56) 138 (44)
APRIc score: <0.0001
< 0.5 409 (31) 206 (50) 203 (50)
0.5–1.5 426 (32) 312 (73) 114 (27)
> =1.5 195 (15) 155 (79) 40 (21)
Unknown 279 (21) 146 (52) 133 (48)
Decline in haemoglobin (g/dl) 0.0017
No decline 179 (14) 126 (70) 53 (30)
< =2.5 227 (17) 157 (69) 70 (31)
> 2.5 230 (18) 127 (55) 103 (45)
Missing 637 (49) 409 (64) 264 (41)
Duration of HCV treatment in weeks <0.0001
< =24 496 (38) 390 (79) 106 (21)
24-48 437 (33) 242 (55) 195 (45)
> 48 376 (29) 187 (50) 189 (50)
Calendar year of start HCV treatment <0.0001
< =2003 266 (20) 201 (76) 65(24)
2003–2006 421 (32) 258 (61) 163 (39)
> =2006 622 (48) 360 (58) 262 (42)
cART regimen 0.003
PI 158 (12) 104 (66) 54 (34)
Boosted PI 444 (34) 296 (67) 148 (33)
NNRTI 284 (22) 154 (54) 130 (46)
PI + NNRTI 50 (6) 35 (70) 15 (30)
No PI and/or NNRTI 131 (10) 90 (69) 41 (31)
no cART 242 (18) 140 (58) 102 (42)
Backbone <0.0001
Start after HCV treatment 242 (18) 140 (58) 102 (42)
ABC + 3TC 189 (14) 117 (62) 72 (38)
AZT + 3TC 140 (11) 99 (62) 41 (29)
FTC + TDF 262 (20) 147 (56) 115 (44)
TDF + 3TC 130 (10) 68 (52) 62 (48)
TDF + ABC 44 (3) 27 (61) 17 (39)
d4T + 3TC 90 (7) 68 (76) 22 (24)
other 212 (16) 153 (72) 59 (28)
apercentage in these colums are representing the percentage of the total number of patients in a specific category/row
bPercentage from total number of patients included in this study (n = 1309)
cAPRI, aspartate amino transferase-to-platelet ratio; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase; NRTI, nucleoside analog reverse-transcriptaseinhibitor;
ABC, abacavir, 3TC, lamivudine; AZT, zidovudine; FTC, emtricitabine; TDF, tenofovir; d4T, stavudine
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Table 2 Association of predictive factors with sustained virologic response among patients receiving anti-hepatitis C virus (HCV)
treatment in chronically HCV/HIV co-infected patients, COHERE collaboration, 1998–2011, using logistic regression with forward
selection of the variables included in the multivariate model
Univariate p-value Multivariate p-value
Odds ratio (95 %
confidence interval)
Odds ratio (95 %
confidence interval)
Age at start HCV treatment (years) 16–34 1 1
35–49 0.71 (0.51–0.99) 0.04 0.80 (0.52–1.23) 0.29
> = 50 0.68 (0.43–1.07) 0.10 0.58 (0.32–1.04) 0.06
Duration HCV treatment in weeks <24 1 1
24–48 2.97 (2.23–3.95) <0.0001 2.85 (2.0–4.05) <0.0001
>48 3.72 (2.77–4.99) <0.0001 4.92 (3.43–7.08) <0.0001
Calendar year of starting HCV treatment <=2003 0.45 (0.32–0.64) <0.0001 0.41 (0.29–0.71) 0.0008
2003–2005 0.90 (0.69–1.18) 0.27 1.10 (0.78–1.59) 0.62
> = 2006 1 1
BMI <25 1 1
> = 25 0.69 (0.42–1.13) 0.14 1.01 (0.58–1.76) 0.97
unknown 1.85 (1.41–2.44) <0.0001 6.12 (3.99–9.38) <0.0001
Gender Male 1 0.57 -
Female 1.08 (0.84–1.38)
HIV transmission route: MSM 1.80 (1.28–2.53) 0.0008 -
Male injection drug us (IDU) 1
Female IDU 1.26 (0.91–1.74) 0.17
Male heterosexual 1.03 (0.63–1.66) 0.92
Female heterosexual 1.07 (0.68–1.68) 0.77
Male other/unknown 1.18 (0.77–1.81) 0.45
Female other/unknown 1.48 (0.80–2.75) 0.21
Region of origin: Western 1 -
Other 1.07 (0.72–1.58) 0.75
Unknown 1.67 (1.09–2.56) 0.02
HIV RNA levels at baseline (copies/ml) <=400 1.00 (0.74–1.34) 0.99 -
>400 1
Hepatitis B virus co-infection No 1 -
Yes 1.29 (0.74–2.25) 0.37
unknown 0.94 (0.49–1.78) 0.58
Nadir CD4 (cells/μl) <200 1 1
> = 200 0.90 (0.72–1.14) 0.38 0.80 (0.57–1.12) 0.19
CD4 at baseline (cells/μl) 0–349 1 1
350–499 0.93 (0.66–1.31) 0.68 0.69 (0.45–1.07) 0.09
> = 500 1.14 (0.84–1.54) 0.40 0.94 (0.62–1.42) 0.75
missing 0.69 (0.48–0.99) 0.04 0.10 (0.05–0.19) <0.0001
HCV RNA load at baseline <600,000 2.52 (1.86–3.43) <0.0001 2.06 (1.38–3.06) 0.0004
≥600,000 1 1
missing 1.11 (0.85–1.44) 0.46 1.41 (0.90–2.20) 0.13
HCV genotypes 1 0.52 (0.32–0.87) 0.02 0.27 (0.14–0.51) <0.0001
1a 0.35 (0.25–0.50) <0.0001 0.25 (0.17–0.39) <0.0001
1b 0.35 (0.23–0.53) <0.0001 0.28 (0.16–0.47) <0.0001
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treatment remained significantly associated with a lower
odds of achieving an SVR.
Discussion
The results of this study, conducted in an unselected co-
hort of HCV/HIV co-infected patients from different
countries in Europe, showed no difference in response
to HCV treatment in patients using an ABC-containing
regimen compared to those using an FTC + TDF-con-
taining backbone. Overall, 37 % of patients achieved an
SVR, compared to 29 % of patients on a boosted PI regi-
men. The response to HCV treatment did not differ be-
tween patients who used cART and those who did not.
Earlier studies have shown contradicting results for
the effect of ABC [2, 3, 6–8]. The results of our study,
conducted in a large multi-cohort study, validate those
of an earlier large cohort study into the effect of cART
on HCV treatment outcome [9]. In our study, the
concomitant use of ABC + 3TC or ABC + TDF and HCV
treatment did not result in different SVR rates compared
to the concomitant of TDF + FTC and HCV treatment,
which was most frequently used in this patient popula-
tion. In terms of the NRTIs used during HCV treatment,
in this study AZT in combination with 3TC and d4T in
combination with 3TC negatively affected the response
to HCV treatment. This negative effect of these NRTIs
might be due not only to the interference of d4T with
RBV [11], but also the effect of AZT on lowering haemo-
globin levels [12]. Moreover, according to the guidelines
from the European AIDS Clinical Society, d4T and AZT
use should be avoided during pegIFN and RBV treatment
[13], as both PEG-IFN and RBV are also commonly
known to decrease haemoglobin levels [14, 15]. In fact, an-
aemia is frequently observed in patients during HCV ther-
apy [12] and is often a cause for RBV dose reductions or
early discontinuation of HCV treatment, which negatively
Table 2 Association of predictive factors with sustained virologic response among patients receiving anti-hepatitis C virus (HCV)
treatment in chronically HCV/HIV co-infected patients, COHERE collaboration, 1998–2011, using logistic regression with forward
selection of the variables included in the multivariate model (Continued)
2 & 3 1 1
4 0.37 (0.24–0.60) <0.0001 0.32 (0.19–0.54) <0.0001
Other/unknown 0.74 (0.55–1.02) 0.69 0.70 (0.46–1.05) 0.023
APRIa score <0.5 1 1
0.5–1.5 0.37 (0.28–0.50) <0.0001 0.41 (0.29–0.58) <0.0001
> = 1.5 0.26 (0.18–0.39) <0.0001 0.24 (0.15–0.39) <0.0001
unknown 0.92 (0.68–1.25) 0.61 0.61 (0.40–0.94) 0.023
Decline in haemoglobin (g/dl) No decline 1 1
<=2.5 1.06 (0.69–1.62) 0.78 0.89 (0.52–1.51) 0.66
>2.5 1.93 (1.28–2.92) 0.002 1.36 (0.81–2.28) 0.24
missing 1.53 (1.08–2.19) 0.02 4.66 (2.81–7.72) <0.0001
cART use: PI 0.62 (0.41–0.92) 0.02 1.04 (0.62–1.75) 0.87
Boosted PI 0.59 (0.44–0.80) 0.0008 0.61 (0.41–0.91) 0.02
NNRT 1 1
PI + NNRT 0.51 (0.27–0.97) 0.04 0.65 (0.29–1.44) 0.29
No PI and/or NNRT 0.54 (0.39–0.84) 0.006 0.78 (0.44–1.39) 0.39
Start after HCV treatment 0.86 (0.61–1.22) 0.40 NAb
NRTI backbonea Start after HCV treatment 0.93 (0.65–1.33) 0.69 0.96 (0.57–1.61) 0.34
ABC + 3TC 0.79 (0.54–1.15) 0.22 0.74 (0.45–1.24) 0.25
AZT + 3TC 0.53 (0.34–0.82) 0.004 0.44 (0.24–0.80) 0.007
FTC + TDF 1 1
TDF + 3TC 1.17 (0.76–1.78) 0.47 0.76 (0.44–1.32) 0.33
TDF + ABC 0.81 (0.42–1.55) 0.51 0.79 (0.35–1.78) 0.57
d4T + 3TC 0.41 (0.24–0.71) 0.001 0.46 (0.22–0.96) 0.04
other 0.50 (0.34–0.73) 0.0003 0.54 (0.32–0.91) 0.02
aAPRI, aspartate amino transferase-to-platelet ratio; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase; NRTI, nucleoside analog reverse-transcriptaseinhibitor;
ABC, abacavir, 3TC, lamivudine; AZT, zidovudine; FTC, emtricitabine; TDF, tenofovir; d4T, stavudine
bOdds ratio could not be calculated due to collinearity with the NRTI backbone category ‘start after HCV treatment’
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impacts SVR rates [16]. On the other hand, lower haemo-
globin levels have been shown to be associated with higher
SVR rates [17]. This could reflect adequate weight-based
RBV dosing accompanied by more side effects such as de-
clining haemoglobin levels. Although we had no data on
RBV dosing, haemoglobin measurements were available
for half the patients. Consequently, we were able to calcu-
late changes in haemoglobin levels and to use the decline
in haemoglobin levels as a proxy for changes in RBV
doses, assuming that a stronger decline in haemoglobin
levels might be a marker for higher RBV doses. As a result
of including this haemoglobin change in our analyses we
observed higher SVR rates in patients with a haemoglobin
decline of 2.5 g/dl or more from baseline, which could re-
flect higher RBV levels. In addition, the results of a sensi-
tivity analysis including patients with a haemoglobin
decline of >2.5 g/dl showed that patients using the com-
bination of AZT and 3TC remained less likely to achieve
an SVR compared to patients who used FTC +TDF.
Although this result was not statistically significant, the
effect of AZT on lowering haemoglobin levels could have
attributed to higher toxicity and early discontinuation.
Several reports have shown that weight-based dosing of
RBV is more effective than flat dosing of RBV, and that ad-
equate dosing of RBV is crucial to maximising HCV treat-
ment response [18, 19]. Consequently, there has been a
shift from flat dosing to weight-based dosing over time,
with most patients receiving weight-based RBV from 2006
onwards. To account for this shift and address the lack of
information on RBV dosing in our study, we included
calendar time of starting HCV treatment.
The composition of cART regimens has changed over
time. In recent years, there has been a drop in the use of
AZT and d4T in cART regimens; in fact the European
AIDS clinical society guidelines no longer recommend
inclusion of AZT and d4T in initial regimens [13]. More-
over, with the introduction of the HIV integrase inhibitor
dolutegravir, use of ABC in combination with 3TC is ex-
pected to increase in the future. Therefore, to evaluate the
impact of these changes over calendar time we included
an interaction term between calendar time and NRTI
backbones in the logistic regression model. This analysis
found no statistically significant interaction and therefore
we assumed that the effect of cART regimens on HCV
treatment response does not vary with calendar time.
Our study found a significantly lower SVR in patients
on a boosted PI regimens compared to those on an
NNRTI-based regimen. This confirms previous reports
of an association between a PI-based regimen and lower
SVR rates [20]. Furthermore, Berenguer et al. also found
that patients on a boosted PI were less likely to achieve
an SVR, although this result was statistically non-
significant [9]. The significant difference between a
boosted PI-based regimen and an NNRTI-based regimen
in our study might be due to differences in patient char-
acteristics in the two groups: patients on a boosted PI-
based regimen had significant lower CD4 counts at the
time of cART initiation than patients on an NNRTI
cART regimen. Since boosted PI regimens are likely to
be prescribed to patients who experienced virological
failure on earlier cART regimens, these patients may
have been infected with HIV for a longer period of time
and may have had more advanced HIV disease progres-
sion. It is also likely that these patients had been chron-
ically infected with HCV for a longer period of time. As
a result, these patients may have had a higher degree of
liver damage, as progression to liver disease is common
with HCV and known to be accelerated in the presence
of HIV [21, 22], and therefore might have been less
likely to achieve an SVR [23]. To account for the pro-
gression to liver disease and for advanced HIV disease,
in the final multivariate model we included not only the
APRI score, which has been shown to be a reliable
marker for predicting hepatic fibrosis in HIV/HCV co-
infected patients [10], but also nadir CD4 cell count.
After adjustment for differences in advanced HIV and
liver disease, our study still shows a trend towards a
lower probability of achieving an SVR in patients on a
boosted PI regimen. Furthermore, although not statisti-
cally significant, the discontinuation rate of HCV treat-
ment was somewhat higher in patients receiving a PI or
PI-boosted cART regimen, compared to patients receiv-
ing an NNRTI cART regimen.
The primary aim of our study was to examine the in-
fluence of ABC on the response to pegIFN and RBV-
containing HCV treatment in patients already receiving
cART prior to HCV treatment. However, we also in-
cluded a group of patients who started cART after re-
ceiving HCV treatment. When we compared this group
to those who were already using an FTC + TDF-contain-
ing backbone prior to starting HCV treatment, we found
no statistically significant difference in SVR response
rates. An explanation for this finding could be that the
group of patients who started cART after HCV treat-
ment were relatively healthy and not yet in need for HIV
treatment. This assumption is supported by the large
number of these patients with a high CD4 cell count at
the time of HCV treatment initiation: median CD4 cell
count in this group was 494 cells/mm3 (interquartile
range: 387–651).
Finally, the number of new DAAs is increasing and,
consequently, the number of treatment options that rule
out the need for pegIFN will also increase substantially.
In view of this development, the interaction between
pegIFN and ABC has become less relevant. Furthermore,
as the result of the growing number of treatment op-
tions, including DAA combinations without RBV, it is
also likely that fewer patients will be treated with a RBV-
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containing DAA combination in the future, which might
limit the clinical importance of the present findings.
Nonetheless, we believe knowledge regarding a possible
interaction between RBV and ABC remains important as
some of the new DAAs may still be used in combination
with RBV. Moreover, the high costs of these new DAAs
could limit access to these treatment options in some re-
gions, which might result in RBV still being used in
combination with ABC in certain settings.
Conclusions
The results of this large European cohort study validate
those of another large cohort study by showing that SVR
rates are generally not affected by ABC. Use of d4T or
AZT as part of the HIV treatment regimen was associated
with a lower likelihood of achieving an SVR, which, in the
case of AZT, might be related to its propensity to induce
anaemia. A potential negative impact of a boosted PI regi-
men may warrant further evaluation. Finally, we found no
evidence of a harmful effect of ABC-containing regimens
in future DAA and RBV combinations.
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